Professor Tore Bengtsson's Breakthrough Research on Metabolic Disease Published in Cell

Written By Muhammad Hamza Bokhari

We are proud to announce a pivotal milestone for Professor Tore Bengtsson, with the publication of a landmark study in the prestigious journal Cell. This work validates a new therapeutic paradigm pioneered by Prof. Bengtsson and developed by Atrogi AB.

The paper unveils ATR-258, a first-in-class oral drug that precisely activates skeletal muscle metabolism. It solves a long-standing challenge by using novel GRK2-biased signaling to deliver powerful benefits while avoiding the cardiovascular risks of conventional β2-agonists.

A Solution for Healthier Weight Loss

Critically, this research provides a solution to the muscle-wasting problem seen with current incretin therapies (GLP-1s). The approach is proven to reshape body composition—reducing fat while preserving and building vital muscle mass—paving the way for truly healthy weight loss.

This breakthrough is validated by:

  • Extensive preclinical data in models of diabetes, obesity, and sarcopenia.

  • A strong safety profile from long-term toxicology studies.

  • A successful first-in-human Phase 1 trial confirming safety and tolerability.

This landmark study, appearing in the September 2025 issue of Cell, is the product of a powerful academic-industry partnership. The collaboration, led by Atrogi, included experts from Karolinska Institutet, Stockholm University, and other leading institutions across Europe and Australia.

Learn More:

  • Read the full publication in Cell: https://www.cell.com/cell/fulltext/S0092-8674(25)00630-0

  • Read the official press release: https://atrogi.com/2025/06/24/atrogi-announces-cell-paper-highlighting-transformative-potential-of-muscle-targeted-therapy-in-metabolic-disease/

Muhammad Hamza Bokhari